Skip to main content
Clinical Trials/ISRCTN45828668
ISRCTN45828668
Completed
Not Applicable

A phase I - II, prospective, double blind, randomised study of the safety and efficacy of sulfasalazine for the treatment of progressing malignant gliomas

niversity of Liege, Department of Neurosurgery (Belgium)0 sites20 target enrollmentDecember 15, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Progressive malignant glioma (astrocytic)
Sponsor
niversity of Liege, Department of Neurosurgery (Belgium)
Enrollment
20
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 15, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Liege, Department of Neurosurgery (Belgium)

Eligibility Criteria

Inclusion Criteria

  • 1\. Adult patients aged greater than 18 years
  • 2\. With recurrent or progressive World Health Organization (WHO) grade 3 or 4 astrocytic gliomas after surgery
  • 3\. Standard radiation therapy
  • 4\. A first line of conventional chemotherapy (e.g. temozolomide, CCNU or BCNU)
  • Recurrence or progression prior to inclusion are based on MacDonald?s criteria. Patients are thoroughly informed about the nature of their disease, suspected prognosis, study background and objectives and potential alternative treatments. This information is provided both orally and in written form, prior to obtaining written informed consent from the patient.

Exclusion Criteria

  • 1\. Present with anaplastic oligodendroglioma (WHO grade 3\)
  • 2\. Allergy to sulfa drugs
  • 3\. Porphyria
  • 4\. G\-6\-PD deficiency
  • 5\. Psychiatric disorder deemed incompatible with compliance to the study
  • 6\. Creatinine greater than 15 mg/l
  • 7\. Aspartate aminotransferase (TGO) greater than 200 UI/l
  • 8\. Amylase greater than 150 UI/l
  • 9\. Pregnant or lactating women
  • 10\. Patients may not have received any other experimental medication within 30 days (and at least five drug half\-lives) prior to inclusion

Outcomes

Primary Outcomes

Not specified

Similar Trials